Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Cefiderocol/Xeruborbactam in Renal Impairment
NCT07104162Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of xeruborbactam + cefiderocol in bacterial infection (5 arms), sponsored by Qpex Biopharma. Primary endpoints: Incidence of treatment-emergent adverse events, Changes from baseline in safety parameters and 5 more. Started Sep 2025; status: completed.
02
Drugs
xeruborbactam + cefiderocol
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07104162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104162.